These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 33575214)
1. MRD Tailored Therapy in AML: What We Have Learned So Far. Ngai LL; Kelder A; Janssen JJWM; Ossenkoppele GJ; Cloos J Front Oncol; 2020; 10():603636. PubMed ID: 33575214 [TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661 [TBL] [Abstract][Full Text] [Related]
3. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
5. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Tettero JM; Al-Badri WKW; Ngai LL; Bachas C; Breems DA; van Elssen CHMJ; Fischer T; Gjertsen BT; van Gorkom GNY; Gradowska P; Greuter MJE; Griskevicius L; Juliusson G; Maertens J; Manz MG; Pabst T; Passweg J; Porkka K; Löwenberg B; Ossenkoppele GJ; Janssen JJWM; Cloos J Front Oncol; 2022; 12():999822. PubMed ID: 36300090 [TBL] [Abstract][Full Text] [Related]
11. The role of multiparameter flow cytometry for disease monitoring in AML. Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037 [TBL] [Abstract][Full Text] [Related]
12. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. Caballero-Velázquez T; Pérez-López O; Yeguas Bermejo A; Rodríguez Arbolí E; Colado Varela E; Sempere Talens A; Vidriales MB; Solé-Rodríguez M; Quirós Caso C; Pérez López E; Reinoso Segura M; Prats-Martín C; Montesinos P; Pérez-Simón JA Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900400 [TBL] [Abstract][Full Text] [Related]
14. MRD in Venetoclax-Based Treatment for AML: Does it Really Matter? Bernardi M; Ferrara F; Carrabba MG; Mastaglio S; Lorentino F; Vago L; Ciceri F Front Oncol; 2022; 12():890871. PubMed ID: 35924144 [TBL] [Abstract][Full Text] [Related]
15. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
16. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Venditti A; Buccisano F; Del Poeta G; Maurillo L; Tamburini A; Cox C; Battaglia A; Catalano G; Del Moro B; Cudillo L; Postorino M; Masi M; Amadori S Blood; 2000 Dec; 96(12):3948-52. PubMed ID: 11090082 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia. Canali A; Vergnolle I; Bertoli S; Largeaud L; Nicolau ML; Rieu JB; Tavitian S; Huguet F; Picard M; Bories P; Vial JP; Lechevalier N; Béné MC; Luquet I; Mansat-De Mas V; Delabesse E; Récher C; Vergez F Clin Cancer Res; 2023 Jan; 29(1):134-142. PubMed ID: 36318706 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation]. Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041 [No Abstract] [Full Text] [Related]
19. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P; Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859 [TBL] [Abstract][Full Text] [Related]
20. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. Dix C; Lo TH; Clark G; Abadir E J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32503122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]